drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T cells)
drug_description
Autologous TCR-engineered T cells (TCR-T) expressing an NY-ESO-1–specific, HLA-A2–restricted T-cell receptor to recognize NY-ESO-1 peptides on HLA-A2 and kill tumor cells via TCR-mediated cytotoxicity.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express an NY-ESO-1–specific, HLA-A2–restricted T-cell receptor. They recognize NY-ESO-1 peptide presented on HLA-A2 on tumor cells and, upon TCR engagement, activate and kill target cells via perforin/granzyme-mediated cytotoxicity and associated effector functions.
drug_name
TC-N201
nct_id_drug_ref
NCT05881525